Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford South University Medical Center — Fargo, North Dakota
- Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
- Sanford Medical Center Fargo — Fargo, North Dakota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
- Altru Cancer Center — Grand Forks, North Dakota
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 2 Recruiting Industry
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in North Dakota: - Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naï…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165070
Sites in North Dakota: - Sanford Fargo Medical Center ( Site 0039) — Fargo, North Dakota
Phase 2 Recruiting Industry
Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this st…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07252739
Sites in North Dakota: - Sanford Health Roger Maris Cancer Center ( Site 0039) — Fargo, North Dakota
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford South University Medical Center — Fargo, North Dakota
- Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
- Sanford Medical Center Fargo — Fargo, North Dakota
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in North Dakota: - Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in North Dakota: - Essentia Health — Fargo, North Dakota
- Trinity Hospital Cancer Care Center — Minot, North Dakota
Recruiting Industry
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-c…
Sponsor: Freenome Holdings Inc.
NCT ID: NCT06122077
Sites in North Dakota: - Altru Health System — Grand Forks, North Dakota